As Smith & Nephew shares tumble, is it time to buy?

The Smith & Nephew shares led the FTSE 100 loser board this morning after a trading update. Does this offer our writer a buying opportunity?

| More on:
A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market did not like a trading update from medical devices manufacturer Smith & Nephew (LSE: SN) released this morning (31 October). As I write on Thursday afternoon, Smith & Nephew shares are down 12% from the closing price yesterday. That makes it the biggest faller of any FTSE 100 share in morning trading.

Does this offer me a possible buying opportunity as a long-term investor?

Disappointing update

In its third-quarter trading update, the company reported 4% growth compared to the same period last year.

That might sound good and certainly not a reason for Smith & Nephew shares to fall. But it disappointed investors.

The company said that, “China was impacted by worse than expected headwinds across our surgical businesses”. It also lowered its full-year underlying revenue growth expectation to around 4.5%, versus 5-6% previously.

Created using TradingView

Again, that might not sound like a big change.

But bear in mind that we are already over three-quarters of the way through the year, so changing full-year expectations at this point suggests there may be sharply weaker performance still to come in the current quarter.

Will things get better or worse?

I am not persuaded management has really got a handle on how to get the business on track to hit its ambitious growth goals.

In the statement, the company said, “While the revised outlook reflects the headwinds across our surgical businesses in China, we remain convinced that our transformation to a higher growth company… is on the right course“.

In my experience, pinning a sales warning on a single part of the business often foreshadows more widespread challenges. In the quarter, for example, the orthopaedics revenue grew 2.4%. That strikes me as perfectly decent, but it is not the sort of growth I would get excited about if I wanted to invest in a “higher growth company”.

Smith & Nephew’s price-to-earnings ratio of 17 does not seem cheap to me. If the company issues further bad news or underperforms expectations in the fourth quarter or next year, I think it could merit a lower valuation. Earnings per share have declined markedly in recent years.

Created using TradingView

The business does have strengths: a large, resilient target customer market, an established base of buyers, and proprietary technology.

Even just bringing earnings per share back to where they stood a few years ago could help justify a higher price for Smith & Nephew shares.

No rush to buy

But, as the trading statement underlined, there is work to be done.

My concern is that there is more of it to be done that management may currently realise. Having set itself lofty growth goals in recent years, I remain unconvinced as to whether the business can deliver them.

I am thus in no rush to buy the shares and will instead wait to see how the business performs in coming months and beyond.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

C Ruane has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

Here are the best-performing S&P 500 stocks after the US election result

Jon Smith notes some of the largest gainers from the S&P 500 yesterday and explains how the election result has…

Read more »

Growth Shares

2 UK stocks knocking on the door of promotion to the FTSE 100

Jon Smith points out a couple of UK stocks that he feels could be ready for the big league based…

Read more »

Investing Articles

Rolls-Royce shares just fell 7%. Is it time to buy?

This investor in Rolls-Royce shares takes a look at the FTSE 100 engine maker's trading update to see what caused…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

What’s going on with the Auto Trader share price?

Paul Summers takes a closer look at why the Auto Trader share price has tumbled despite the company posting higher…

Read more »

Investing Articles

Legal & General shares look set to give me a mind-blowing 10.22% yield in 2026!

Harvey Jones is getting a brilliant second income from his Legal & General shares and expects even more to come.…

Read more »

Investing Articles

I’d consider this beaten-down FTSE 100 dividend stock to target a second income of £19,000

Our writer sees an opportunity to earn a substantial second income by investing in this UK insurance giant. Here’s his…

Read more »

Investing Articles

How cheap is the 72p Vodafone share price?

The Vodafone share price looks very cheap having fallen to a 72p price tag. But is it really the bargain…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Up 43% in a year and the IAG share price could keep on rising!

One of the FTSE 100’s highest-flying stocks still looks cheap on an earnings basis. Is this a brilliant buy for…

Read more »